瘤透淋巴细胞治疗的进展和前景
Xu Qiu1, Shengjun Li2, Tianyu Fan1,3
1The Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China.
Discover oncology
|November 8, 2024
概括
瘤透淋巴细胞 (TIL) 疗法通过利用持久的,瘤特异性的T细胞,显示出持久的癌症回归. 目前正在进行的研究优化了这种采用性T细胞疗法,以克服挑战并增强其在免疫治疗中的潜力.
科学领域:
- 免疫学和癌症治疗疗法
- 基于细胞的免疫疗法
背景情况:
- 使用瘤透性淋巴细胞 (TILs) 的采用性T细胞疗法 (ACT) 已经在各种瘤类型中证明了持久的癌症回归.
- TILs是识别各种瘤抗原的多克隆效应T细胞,提供了一个有前途的治疗策略.
- 在体外扩展TILs可以减轻瘤微环境的抑制作用.
研究的目的:
- 审查TIL疗法的当前进展.
- 识别和讨论TIL治疗的基于问题的优化策略.
- 为下一代TIL治疗提供增强癌症免疫治疗的未来前景.
主要方法:
- 对TIL隔离,修改,扩展和患者输液的现有文献的审查.
- 在TIL治疗方案中分析当前的挑战和建议的解决方案.
- 探索改善TIL血统分化和瘤贩运的策略.
主要成果:
- TIL治疗表现出显著的临床活性,持续的客观反应和有利的安全性.
- 在TIL扩展和工程方面的进展对于治疗疗效至关重要.
- 需要优化策略来解决过程复杂性,并增强TIL对瘤的定位.
结论:
- TIL疗法是一种强效的采用T细胞疗法,在癌症治疗中具有经过验证的记录.
- 持续优化TIL治疗方案对于最大限度地提高其临床效益至关重要.
- 未来的方向侧重于下一代TIL疗法,以进一步增强基于细胞的癌症免疫疗法.
相关概念视频
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K